无乳链球菌荚膜多糖疫苗的研究进展  

Research progress in Streptococcus agalactiae capsular polysaccharide(CPS)vaccines

作　　者：陈晶[1] 范钊玮 马骏 崔玉东[1] CHEN Jing;FAN Zhao-wei;MA Jun;CUI Yu-dong(College of Life Science and Technology,Heilongjiang Bayi Agricultural University,Daqing 163319,China)

机构地区：[1]黑龙江八一农垦大学生命科学技术学院,大庆163319

出　　处：《中国人兽共患病学报》2022年第11期1001-1006,共6页Chinese Journal of Zoonoses

基　　金：黑龙江省科学基金委重点项目(No.ZD2016004);黑龙江八一农垦大学“三横三纵”团队项目(No.TDJH201810);黑龙江八一农垦大学博士启动基金(XDB-2017-17);黑龙江省重点研发计划项目(No.GZ20210101)。

摘　　要：无乳链球菌(Streptococcus agalactiae)是一种分布广泛的人兽共患性致病菌。新生儿感染可引起致命性的败血症和脑膜炎。母体免疫是预防新生儿无乳链球菌感染的最有前景的有效策略。然而,目前尚无可用的疫苗。作为无乳链球菌最重要的毒力因子之一,荚膜多糖(CPS)被认为是开发无乳链球菌疫苗的主要靶标。在此,我们综述了无乳链球菌CPS疫苗和CPS-蛋白结合疫苗的研究概况以及最新进展,旨在为无乳链球菌疫苗的研究提供参考。Streptococcus agalactiae is a widely distributed zoonotic pathogen,which often causes neonatal infections,fatal septicemia,and meningitis.Maternal immunization is the most promising and effective strategy for preventing S.agalactiae infection in neonates.However,no vaccine is currently available.Capsular polysaccharide(CPS),one of the most important virulence factors of S.agalactiae,is considered the best target for the development of S.agalactiae vaccines.This review provides an overview of the recent progress in S.agalactiae CPS vaccines and CPS-protein conjugate vaccines,to serve as a reference and to support new insights in the study of S.agalactiae vaccines.

关 键 词：无乳链球菌 荚膜多糖 疫苗 研究进展 

分 类 号：R378.1[医药卫生—病原生物学]